What is SION's preferred stock, par or stated value per share?

SION (SION) reported preferred stock, par or stated value per share of $0 in Q1 2026.

How has SION's preferred stock, par or stated value per share changed year-over-year?

SION's preferred stock, par or stated value per share decreased by 0.0% year-over-year, from $0 to $0.

Vertex PharmaceuticalsVRTX

——

BioCryst PharmaceuticalsBCRX

——

Denali Therapeutics Inc.DNLI

——

Neurocrine BiosciencesNBIX

——

Operating income-$29.6M-50.6%

Net income-$26.8M-62.5%

EPS (diluted)-$0.60+3.2%

Cash & equivalents$64.3M-23.2%

Total debt$8.4M-11.8%

Total equity$288.2M-18.1%

Total assets$305.0M-17.5%

Operating cash flow-$21.8M-34.1%

CapEx--100%

Free cash flow-$21.8M-33.4%

Market cap$1.86B—

Return on equity-26.7%—

Debt / equity0×0.0×

Current ratio22.6×-6.1×

Reported directly by SION in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.

The official record: SION’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is SION's preferred stock, par or stated value per share?: SION (SION) reported preferred stock, par or stated value per share of $0 in Q1 2026.
How has SION's preferred stock, par or stated value per share changed year-over-year?: SION's preferred stock, par or stated value per share decreased by 0.0% year-over-year, from $0 to $0.